Sep 22, 2023
La Jolla Labs Mentioned in 1STRAND Article Titled: San Diego's RNA Cluster
La Jolla Labs partner, 1STRAND, quotes CEO of La Jolla Labs, Jeff Milton in article discussing San Diego's RNA cluster.
Aug 30, 2023
LJSplice (OpenAccess) is Released!
Our new ML models provide a roadmap for designing optimal splicing screens for antisense therapeutics.
Aug 24, 2023
Discussion Panelist at Invest in Cures San Diego 2023
La Jolla Labs CEO, Jeff Milton, joined the Innovation in Rare Disease Panel Discussion during LaunchBio's Invest In Cures Event to discuss how computational biology and machine learning may be used to address the unmet needs of rare disease patients.
Jul 27, 2023
La Jolla Labs Featured in Article about Rare Disease Drug Discovery.
"This is not a science problem anymore’: Paths emerge for scaling up rare disease medicine"(ENDPOINT NEWS).
Jul 10, 2023
La Jolla Labs Partners with Pitt Hopkins Research Foundation: Investigating the Feasibility of ASO Therapy in Pitt Hopkins Syndrome
"ASOs are an established class of drug showing increasing success in treating neurological diseases. To determine if ASOs would make good therapeutics for Pitt Hopkins Syndrome (PHS), the PHRF has arranged a collaboration with Mahzi Therapeutics and La Jolla Labs. Currently, this project is in the very early phases of scientific development, working to establish proper biological systems to evaluate this strategy. Once experimental conditions are worked out, this collaboration will test the ability of ASOs to restore the protein levels of TCF4 and effectively reverse the cause of PTHS" (Pitt Hopkins Research Foundation).
Jun 24, 2023
KIF1A.ORG Features LJL's Revealing Rare Genes Blog in Rare Roundup
"Looking for a refresher on KIF1A and KAND? This week La Jolla Labs featured KAND in its Revealing Rare Genes blog with input from KIF1A.ORG. This article provides an excellent overview of the history and biology of KAND with a focus on therapeutic development, so we’ll let it speak for itself. A huge thank you to Perla Sandoval and Allison Brown for creating this resource"(KIF1A.ORG).
Jun 3, 2023
Who is La Jolla Labs?
Learn more about how La Jolla Labs is developing the world's most efficient RNA drug discovery pipeline.
Jun 1, 2023
ONCE UPON A GENE - EPISODE 189 - Developing Personalized Therapeutics for Ultra Rare Patients with La Jolla Labs CEO Jeff Milton
Tune in to hear Jeff Milton, CEO of La Jolla Labs, join the inspirational Effie Parks on the Once Upon a Gene podcast.
In this episode, they discuss the development of a drug discovery process that opens the doors to a competitive rare disease therapeutics market and isn't trapped behind the walls of "big" pharmaceutical companies.
Mar 1, 2023
La Jolla Labs Lights Up for Rare in Global Chain of Lights on Rare Disease Day
La Jolla Labs participates in the Global Chain of Lights to show support and raise awareness for rare diseases and patients on Rare Disease Day.
Feb 28, 2023
How Artificial Intelligence Will Drive Rare Disease Therapeutics Jeff Milton CEO - La Jolla Labs
Tune in to hear Founder and CEO of La Jolla Labs, Jeff Milton, explain how new artificial intelligence will drive rare disease therapeutics at iXCells Biotechnologies' Rare Disease Day Webinar.
Jan 30, 2023
Jeff Milton, CEO at La Jolla Labs Inc., presented at the N=1 Collaborative Seminar Series: “A Model for Sustainable Discovery in Rare Disease”
Millions of patients world-wide suffer from rare disease and while non-profit organizations provide a platform for certain indications, only a few have succeeded in delivering meaningful therapeutics to patients. To address rare disease in a comprehensive and sustainable manner requires a fundamental change to drug discovery; a change that opens a competitive landscape with risks and rewards that match those found in big pharma. I will present a model that leverages modern technology and the interconnected nature of disease to provide “economic runways” for many rare disease programs.
Dec 20, 2022
They Created a Drug for Susannah. What About Millions of Other Patients?
Today, we have the science to help dying children, but little to no access because our system wasn't designed for medicines for one or very few people. The drug development process may work for large diseases, but to help those with rare diseases, we must now pivot and build a parallel system for individualized medicines.
Oct 21, 2022
Revealing Rare Genes Blog Release
Revealing Rare Genes is a blog covering topics at the intersection of rare diseases and RNA therapeutics. We feature individual diseases, highlight patient stories, and delve into the challenges of bringing these therapies to market. Sometimes science can feel disconnected from the real world and everyday people. Through this blog we aim to forge connections that drive drug development for rare diseases forward: to connect all people with stories to inspire action; scientists with research challenges to overcome; and clinicians with healthcare gaps to address.
Mar 16, 2022
La Jolla Labs and n-Lorem Foundation Partner to Discover Personalized ASO Medicines for Nano-rare Patients
Partnership leverages La Jolla Labs’ automated, high-throughput screening technology to identify optimal ASO candidates.